HROW
HealthcareHarrow Health, Inc. · Drug Manufacturers - Specialty & Generic · $1B
What is Harrow Health, Inc.?
Harrow Health is a small-cap, ophthalmic-focused healthcare company headquartered in Nashville, Tennessee. It operates across pharmaceutical compounding, commercial drug products, and equity stakes in clinical-stage ophthalmology and anesthesia companies.
Harrow Health generates revenue primarily through ImprimisRx, its ophthalmology outsourcing and pharmaceutical compounding business, and through DEXYCU, a commercial product for post-operative eye inflammation. Beyond its direct operations, the company holds equity interests in several clinical-stage companies — including Surface Ophthalmics and Melt Pharmaceuticals — and retains royalty rights tied to drug candidates under development by those partners. This structure blends direct commercial revenue with longer-horizon pipeline exposure.
Harrow Health was incorporated in 2006 and rebranded from Imprimis Pharmaceuticals to its current name in December 2018.
- ImprimisRx ophthalmology compounding and outsourcing services
- DEXYCU post-operative inflammation treatment
- Equity stakes in Surface Ophthalmics and Melt Pharmaceuticals
- Royalty rights on clinical-stage ophthalmic drug candidates
- Eton Pharmaceuticals equity interest and commercial drug exposure
Is HROW a Good Stock to Buy?
UQS Score rates HROW as Below Average overall, reflecting a mixed profile where standout growth is offset by meaningful weaknesses elsewhere.
The Growth pillar is the clearest bright spot in HROW's UQS profile, suggesting the company is expanding its revenue base at a pace that stands out relative to many peers. This growth trajectory is tied to the commercial ramp of its ophthalmic products and the optionality embedded in its pipeline equity stakes.
The Quality, Moat, and Risk pillars all register as Weak, pointing to concerns around earnings durability, competitive defensibility, and balance sheet or operational risk factors that investors should weigh carefully.
See the full pillar breakdown and underlying financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does HROW pay dividends?
No — Harrow Health, Inc. does not currently pay a dividend.
Harrow Health does not currently pay a dividend. For a growth-oriented, small-cap healthcare company still scaling its commercial operations and holding clinical-stage equity interests, retaining capital for reinvestment is the more common strategic posture. Income-focused investors should factor this into their assessment of HROW.
When does HROW report earnings?
Harrow Health reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
The company's Growth pillar rating suggests revenue trends have been moving in a positive direction, though the Weak Quality and Risk ratings indicate that profitability and cash generation remain areas to watch. Investors should review the most recent quarterly results for the latest picture.
For up-to-date earnings results and guidance, visit Harrow Health's investor relations page directly.
HROW Price History
+328.8% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Harrow Health, Inc.?
Based on Harrow Health, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
HROW Long-term Outlook
HROW's Strong Growth pillar suggests the business has meaningful forward momentum, driven by its commercial ophthalmology operations and the potential value embedded in its pipeline equity positions. However, the Weak Risk pillar signals that this growth comes with elevated uncertainty — whether from operational execution, competitive dynamics, or financial structure. The Neutral Valuation pillar suggests the market is pricing in some of this growth without applying an extreme premium or discount. Investors weighing the long-term outlook should balance the genuine growth opportunity against the fragility indicated by the Quality and Risk ratings.
Growth drivers
- Continued commercial expansion of ImprimisRx compounding services
- Potential value realization from clinical-stage equity stakes and royalty rights
- Growing demand for specialized ophthalmic drug products
Key risks
- Weak Quality and Risk pillar ratings signal execution and financial durability concerns
- Clinical-stage pipeline investments carry inherent development and regulatory risk
- Competitive pressure in pharmaceutical compounding and ophthalmology markets
HROW vs Peers
Within the specialty pharmaceutical and healthcare space, HROW competes and is often compared alongside the following companies.
Perrigo is a much larger, diversified consumer self-care and generic pharmaceutical company with a global footprint, contrasting with HROW's narrow ophthalmic focus.
Cronos operates in the cannabis sector, making it a structurally different business, though both share small-cap characteristics and growth-stage risk profiles.
ANI Pharmaceuticals focuses on branded and generic drug commercialization, offering a comparable specialty pharma model but without HROW's ophthalmology-specific concentration.
Frequently Asked Questions
What does Harrow Health do?
Harrow Health is an ophthalmic-focused healthcare company. It operates ImprimisRx, a pharmaceutical compounding and ophthalmology outsourcing business, and commercializes DEXYCU for post-operative eye inflammation. The company also holds equity stakes and royalty rights in several clinical-stage pharmaceutical companies targeting eye diseases and anesthesia.
Does HROW pay dividends?
No, Harrow Health does not currently pay a dividend. The company is in a growth phase and appears to prioritize reinvesting capital into its commercial operations and pipeline equity positions rather than returning cash to shareholders through dividends.
When does HROW report earnings?
Harrow Health follows a standard quarterly earnings cadence for US-listed companies. For the exact timing of upcoming results, check the investor relations section of Harrow Health's official website, as specific dates are subject to change.
Is HROW a good stock to buy?
HROW carries a Below Average UQS Score overall. Its Growth pillar is rated Strong, which is a genuine positive, but the Quality, Moat, and Risk pillars are all rated Weak. That combination suggests meaningful risk alongside the growth opportunity. The full pillar breakdown is available to UQS Pro members.
Is HROW overvalued?
HROW's Valuation pillar is rated Neutral, suggesting the market is neither pricing the stock at an extreme premium nor a deep discount relative to its fundamentals. Whether that represents fair value depends on how an investor weighs the Strong Growth against the Weak Quality and Risk ratings.
How does HROW compare to its competitors?
Compared to peers like Perrigo and ANI Pharmaceuticals, HROW is more narrowly focused on ophthalmology and pharmaceutical compounding. Its small-cap size and clinical-stage equity exposure give it a higher-risk, higher-optionality profile than larger, more diversified specialty pharma companies.
What is HROW's market cap bracket?
Harrow Health is classified as a small-cap company. This places it in a segment of the market that typically carries higher volatility and liquidity risk than mid- or large-cap peers, though small-caps can also offer more pronounced growth potential when execution is strong.
Who founded Harrow Health?
The company was originally incorporated in 2006 as Imprimis Pharmaceuticals. It rebranded to Harrow Health in December 2018. For detailed founding history and leadership background, the company's official investor relations materials are the most reliable source.
Is HROW a long-term quality investment?
From a long-term quality standpoint, HROW's UQS profile presents a mixed picture. The Strong Growth pillar is encouraging, but Weak ratings across Quality, Moat, and Risk suggest the business lacks the durable competitive advantages and financial resilience typically associated with high-conviction long-term holdings. Pro members can view the complete analysis.
What is the main competitive advantage of Harrow Health?
Harrow Health's primary differentiation lies in its specialized focus on ophthalmic pharmaceutical compounding through ImprimisRx and its commercial ophthalmology products. Its equity stakes in clinical-stage companies also provide pipeline optionality. However, the Weak Moat rating suggests these advantages may not yet constitute a durable competitive barrier.
What sector does HROW belong to?
HROW operates in the Healthcare sector, specifically within specialty pharmaceuticals and ophthalmic drug development. Its business spans commercial drug products, pharmaceutical compounding, and equity interests in clinical-stage healthcare companies.
Unlock Full HROW Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar ratings
- ✓Access underlying financial metrics driving each pillar
- ✓Compare HROW against sector peers on quality and risk
- ✓Track Growth and Valuation signals in one dashboard
- ✓Get the complete analyst-grade view for any ticker
Pro Analysis
HROW — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 20, 2026 | 45.9 | 30.7 | 24.0 | 100.0 | 18.9 | 62.7 | -0.6 |
| May 14, 2026 | 46.5 | 30.9 | 24.0 | 100.0 | 18.9 | 66.2 | -1.3 |
| May 10, 2026 | 47.8 | 14.9 | 24.0 | 100.0 | 37.8 | 82.9 | +2.4 |
| May 9, 2026 | 45.4 | 33.0 | 24.0 | 100.0 | 16.3 | 57.9 | -2.3 |
| May 8, 2026 | 47.7 | 14.9 | 24.0 | 100.0 | 37.8 | 82.1 | +2.7 |
| May 7, 2026 | 45.0 | 32.5 | 24.0 | 100.0 | 16.3 | 55.8 | +0.1 |
| May 3, 2026 | 44.9 | 32.5 | 24.0 | 100.0 | 16.3 | 55.3 | -0.1 |
| Apr 26, 2026 | 45.0 | 32.5 | 24.0 | 100.0 | 16.3 | 56.3 | +0.2 |
| Apr 19, 2026 | 44.8 | 32.5 | 24.0 | 100.0 | 16.3 | 54.6 | -0.6 |
| Apr 18, 2026 | 45.4 | 32.5 | 24.0 | 100.0 | 16.3 | 59.1 | -2.4 |
HROW — Pillar Breakdown
Quality
— 30.6/100 (25%)Harrow Health, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 100.0/100 (20%)Harrow Health, Inc. is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 18.9/100 (15%)Harrow Health, Inc. presents elevated risk with concerns around leverage or financial stability.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 60.6/100 (15%)Harrow Health, Inc. trades at a reasonable valuation with decent earnings yield and FCF multiples.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 24/100 (25%)Harrow Health, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for HROW.
Score Composition
Financial Data
More Stock Analysis
How is the HROW UQS Score Calculated?
The UQS (Unified Quality Score) for Harrow Health, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Harrow Health, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Harrow Health, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.